Patient and treatment characteristics
| Characteristics . | All patients (N = 26) . |
|---|---|
| Age, median (range), y | 64 (29-80) |
| Sex, male, n (%) | 19 (73.1) |
| Diagnosis, n (%) | |
| B-ALL | 2 (7.7) |
| DLBCL | 16 (61.5) |
| HGBCL | 2 (7.7) |
| tFL | 6 (23.1) |
| Disease stage at screening, n (%) | |
| Stage I-II | 7 (26.9) |
| Stage III-IV | 17 (65.4) |
| NA | 2 (7.7) |
| Bulky disease at screening, n (%) | |
| No | 20 (76.9) |
| Yes | 5 (19.2) |
| NA | 1 (3.8) |
| Extra nodal sites at screening, n (%) | |
| No | 9 (34.6) |
| Yes | 17 (65.4) |
| Number of extra nodal sites at screening, median (range) | 1 (1-6) |
| CNS localization, n (%) | |
| No | 17 (65.4) |
| Resolved pre-LD | 2 (7.7) |
| Active pre-LD | 7 (26.9) |
| ECOG at screening, n (%) | |
| 0 | 17 (65.4) |
| 1 | 7 (26.9) |
| ≥2 | 2 (7.7) |
| IPI score at screening, n (%) | |
| 0-1 | 8 (30.8) |
| 2 | 7 (26.9) |
| 3 | 3 (11.5) |
| 4-5 | 6 (23.1) |
| NA | 2 (7.7) |
| Previous line of therapy, median (range) | 2 (1-3) |
| Primary refractory to first-line treatment, n (%) | |
| No | 13 (50.0) |
| Yes | 13 (50.0) |
| Primary refractory to second-line treatment, n (%) | |
| No | 10 (38.5) |
| Yes | 16 (61.5) |
| Previous stem cell transplant, n (%) | 11 (42.3) |
| Allogeneic | 2 (7.7) |
| Autologous | 9 (34.6) |
| Response last line of treatment, n (%) | |
| PD | 12 (46.2) |
| SD | 1 (3.8) |
| PR | 1 (3.8) |
| CR | 12 (46.2) |
| Bridging therapy, n (%) | |
| No bridging | 7 (26.9) |
| Radiotherapy | 7 (26.9) |
| Systemic therapy | 5 (19.2) |
| Steroids | 2 (7.7) |
| Combination | 5 (19.2) |
| Response to bridging therapy, n (%) | |
| PD | 9 (34.6) |
| SD | 2 (7.7) |
| PR | 5 (19.2) |
| CR | 3 (11.5) |
| CAR T-cell product, n (%) | |
| Axi-cel | 25 (92.3) |
| Brexu-cel | 2 (7.7) |
| CRP at screening, median (range), mg/L | 6.5 (0.6-78.0) |
| LDH at screening, median (range), U/L | 256.5 (180.0-2024.0) |
| Ferritin at screening, median (range), ng/mL | 660.5 (30.0-1273.0) |
| Missing | 8 |
| EASIX score at screening, median (range) | 1.2 (0.3-22.4) |
| CAR-HEMATOTOX score, median (range) | 2 (1-4) |
| Missing | 6 |
| Comorbidities, n (%) | |
| Atrial fibrillation | 2 (7.7) |
| Atrial flutter | 1 (3.8) |
| Myocardial infarction | 2 (7.7) |
| Melanoma | 2 (7.7) |
| Depression | 1 (3.8) |
| HCT-CI score, n (%) | |
| 0-2 | 24 (92.3) |
| ≥3 | 2 (7.7) |
| Characteristics . | All patients (N = 26) . |
|---|---|
| Age, median (range), y | 64 (29-80) |
| Sex, male, n (%) | 19 (73.1) |
| Diagnosis, n (%) | |
| B-ALL | 2 (7.7) |
| DLBCL | 16 (61.5) |
| HGBCL | 2 (7.7) |
| tFL | 6 (23.1) |
| Disease stage at screening, n (%) | |
| Stage I-II | 7 (26.9) |
| Stage III-IV | 17 (65.4) |
| NA | 2 (7.7) |
| Bulky disease at screening, n (%) | |
| No | 20 (76.9) |
| Yes | 5 (19.2) |
| NA | 1 (3.8) |
| Extra nodal sites at screening, n (%) | |
| No | 9 (34.6) |
| Yes | 17 (65.4) |
| Number of extra nodal sites at screening, median (range) | 1 (1-6) |
| CNS localization, n (%) | |
| No | 17 (65.4) |
| Resolved pre-LD | 2 (7.7) |
| Active pre-LD | 7 (26.9) |
| ECOG at screening, n (%) | |
| 0 | 17 (65.4) |
| 1 | 7 (26.9) |
| ≥2 | 2 (7.7) |
| IPI score at screening, n (%) | |
| 0-1 | 8 (30.8) |
| 2 | 7 (26.9) |
| 3 | 3 (11.5) |
| 4-5 | 6 (23.1) |
| NA | 2 (7.7) |
| Previous line of therapy, median (range) | 2 (1-3) |
| Primary refractory to first-line treatment, n (%) | |
| No | 13 (50.0) |
| Yes | 13 (50.0) |
| Primary refractory to second-line treatment, n (%) | |
| No | 10 (38.5) |
| Yes | 16 (61.5) |
| Previous stem cell transplant, n (%) | 11 (42.3) |
| Allogeneic | 2 (7.7) |
| Autologous | 9 (34.6) |
| Response last line of treatment, n (%) | |
| PD | 12 (46.2) |
| SD | 1 (3.8) |
| PR | 1 (3.8) |
| CR | 12 (46.2) |
| Bridging therapy, n (%) | |
| No bridging | 7 (26.9) |
| Radiotherapy | 7 (26.9) |
| Systemic therapy | 5 (19.2) |
| Steroids | 2 (7.7) |
| Combination | 5 (19.2) |
| Response to bridging therapy, n (%) | |
| PD | 9 (34.6) |
| SD | 2 (7.7) |
| PR | 5 (19.2) |
| CR | 3 (11.5) |
| CAR T-cell product, n (%) | |
| Axi-cel | 25 (92.3) |
| Brexu-cel | 2 (7.7) |
| CRP at screening, median (range), mg/L | 6.5 (0.6-78.0) |
| LDH at screening, median (range), U/L | 256.5 (180.0-2024.0) |
| Ferritin at screening, median (range), ng/mL | 660.5 (30.0-1273.0) |
| Missing | 8 |
| EASIX score at screening, median (range) | 1.2 (0.3-22.4) |
| CAR-HEMATOTOX score, median (range) | 2 (1-4) |
| Missing | 6 |
| Comorbidities, n (%) | |
| Atrial fibrillation | 2 (7.7) |
| Atrial flutter | 1 (3.8) |
| Myocardial infarction | 2 (7.7) |
| Melanoma | 2 (7.7) |
| Depression | 1 (3.8) |
| HCT-CI score, n (%) | |
| 0-2 | 24 (92.3) |
| ≥3 | 2 (7.7) |
Axi-cel, axicabtagene ciloleucel; B-ALL, B-cell acute lymphoblastic leukemia; Brexu-cel, brexucabtagene autoleucel; CAR-HEMATOTOX, chimeric antigen receptor T-cell–related hematologic toxicity; CR, complete response; CRP, C-reactive protein; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; HCT-CI, hematopoietic cell transplant-specific comorbidity index; HGBCL, high-grade large B-cell lymphoma; IPI, integrated pulmonary index; LDH, lactate dehydrogenase; NA, not applicable; PD, progressive disease; PR, partial response; pre-LD, prelymphodepleting chemotherapy; SD, stable disease; tFL, transformed follicular lymphoma.